Apogee Therapeutics (APGE) Insider Trading & Ownership → The only AI company to buy (From Porter & Company) (Ad) Free APGE Stock Alerts $42.12 -1.73 (-3.95%) (As of 06/6/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Apogee Therapeutics (NASDAQ:APGE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage36.10%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$29.75 MNumber OfInsiders Selling(Last 12 Months)0 Get APGE Insider Trade Alerts Want to know when executives and insiders are buying or selling Apogee Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address APGE Insider Buying and Selling by Quarter Ad Brooks EnterprisesHow’d you do in 20222022 was a rough year. At their worst, the S&P 500 was down over 25% and the NASDAQ was down over 35%, and to make things even more interesting the Fed was seemingly raising interest rates every week!Get those kind of results during the Great Financial Crisis, without having to study more Apogee Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/13/2023Nimish P ShahDirectorBuy1,750,000$17.00$29,750,000.00 (Data available from 1/1/2013 forward) APGE Insider Trading Activity - Frequently Asked Questions Who is on Apogee Therapeutics's Insider Roster? The list of insiders at Apogee Therapeutics includes Nimish P Shah. Learn more on insiders at APGE. What percentage of Apogee Therapeutics stock is owned by insiders? 36.10% of Apogee Therapeutics stock is owned by insiders. Learn more on APGE's insider holdings. Which Apogee Therapeutics insiders have been buying company stock? The following insider purchased APGE shares in the last 24 months: Nimish P Shah ($29,750,000.00). How much insider buying is happening at Apogee Therapeutics? Insiders have purchased a total of 1,750,000 APGE shares in the last 24 months for a total of $29,750,000.00 bought. More Insider Trading Tools from MarketBeat Related Companies: RGEN Insider Trading PCVX Insider Trading EXEL Insider Trading RVMD Insider Trading HALO Insider Trading KRYS Insider Trading CRSP Insider Trading IBRX Insider Trading IMVT Insider Trading SWTX Insider Trading Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 3 Small Cap Tech Stocks That Insiders Are Buying3 Stocks Insiders are Buying That Should be on Your RadarInsider Trading is Good News for These Stocks4 Small-Cap Energy Stocks Insiders are Buying 3 Penny Stocks That Insiders Are Buying This page (NASDAQ:APGE) was last updated on 6/6/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredPOTUS in ‘25 Not Biden/Trump, ButAnd I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.